Company intelligence / Profile preview

Blue Jay Ventures

San Mateo, California, USAbluejay.com.au ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

BJT‑778, a fully human IgG1 monoclonal antibody targeting HBsAg, has received EMA PRIME designation based on promising early Phase 1/2 data in HDV. Additional programs include small molecule HBsAg inhibitors and TLR9 agonists, all aiming to achieve functional cure rates for chronic HBV and HDV infections. Clinical development is ongoing with robust investor support and recent major funding rounds.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodySmall moleculeTLR9 agonist (Biologic)
Industry: Biotech

Beyond the preview

Go deeper on Blue Jay Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Jay Ventures.

Explore the full profile